The activity of deoxycytidylate aminohydrolase, a pivotal enzyme for pyrimidine biosynthesis in mammalian tissue, is 100x greater in the Novikoff hepatoma harvested from the intraperitoneal cavity than in the same tumor excised from either subcutaneous or intramuscular sites. The increased enzyme activity in the intraperitoneal tumor is not due to an increase in protein synthesis, since there are no significant differences in enzyme activity between normal liver, and either the subcutaneous or intramuscular hepatomas. Evidence is presented which indicates that deoxycytidylate aminohydrolase activity, and the expression of alternate pathways of pyrimidine biosynthesis in the Novikoff hepatoma, is dependent on the localization of the tumor within the host.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000226832 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Molecular responses of Mytilus coruscus hemocytes to lipopolysaccharide and peptidoglycan as revealed by 4D-DIA based quantitative proteomics analysis.
Fish Shellfish Immunol
January 2025
Laboratory of Marine Biology Protein Engineering, Marine Science and Technical College, Zhejiang Ocean University, Zhoushan City 316022, Zhejiang, China. Electronic address:
Mytilus are sessile filter feeders that live in close contact with numerous marine microorganisms. Hemocytes, the immunocompetent cells of Mytilus, participate in the immune response in a very efficient manner. Lipopolysaccharide (LPS) and peptidoglycan (PGN) follow specific microbe/pathogen-associated molecular patterns (MAMPs or PAMPs) and are involved in immune stimulation in host cells.
View Article and Find Full Text PDFDecitabine cytotoxicity is promoted by dCMP deaminase DCTD and mitigated by SUMO-dependent E3 ligase TOPORS.
EMBO J
June 2024
Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
Article Synopsis
- Decitabine (5-aza-dC) is a nucleoside analogue used for treating certain blood cancers, but its effectiveness can vary and relapses are common.
- Research using CRISPR/Cas9 screens identified that the loss of the enzyme DCTD makes cancer cells resistant to decitabine by reducing the production of 5-aza-dUMP, which is toxic to cells.
- The study revealed that the protein TOPORS helps repair decitabine-induced DNA damage and may be targeted for new biomarkers to predict how patients respond to decitabine treatment.
Computational drug discovery of an inhibitor of APOBEC3B as a treatment for epithelial cancers.
J Biomol Struct Dyn
March 2025
Chemistry Department, Truman State University, Kirksville, MO, USA.
Cancer is one of the leading causes of death in the U.S., and tumorous cancers such as cervical, lung, breast, and ovarian cancers are the most common types.
View Article and Find Full Text PDFFunctional Prokaryotic-Like Deoxycytidine Triphosphate Deaminases and Thymidylate Synthase in Eukaryotic Social Amoebae: Vertical, Endosymbiotic, or Horizontal Gene Transfer?
Mol Biol Evol
December 2023
School of Biological Sciences, University of Nebraska-Lincoln, Lincoln, NE 68588, USA.
The de novo synthesis of deoxythymidine triphosphate uses several pathways: gram-negative bacteria use deoxycytidine triphosphate deaminase to convert deoxycytidine triphosphate into deoxyuridine triphosphate, whereas eukaryotes and gram-positive bacteria instead use deoxycytidine monophosphate deaminase to transform deoxycytidine monophosphate to deoxyuridine monophosphate. It is then unusual that in addition to deoxycytidine monophosphate deaminases, the eukaryote Dictyostelium discoideum has 2 deoxycytidine triphosphate deaminases (Dcd1Dicty and Dcd2Dicty). Expression of either DcdDicty can fully rescue the slow growth of an Escherichia coli dcd knockout.
View Article and Find Full Text PDFA new technique for the analysis of metabolic pathways of cytidine analogues and cytidine deaminase activities in cells.
Sci Rep
November 2023
Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic.
Deoxycytidine analogues (dCas) are widely used for the treatment of malignant diseases. They are commonly inactivated by cytidine deaminase (CDD), or by deoxycytidine monophosphate deaminase (dCMP deaminase). Additional metabolic pathways, such as phosphorylation, can substantially contribute to their (in)activation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!